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Abstract
Background Transcatheter closure of interatrial septal
communications (IASC) is being increasingly performed,
while less is known about predictors and incidence of new
onset atrial ﬁbrillation (AF) after device closure. Hitherto,
most studies have only analyzed some parameters poten-
tially inﬂuencing the occurrence of AF, variously omitting
others and thus limiting interpretation of results.
Methods Descriptive, single author, observational study
with 68 consecutive patients [aged 53.6 ± 15.1 years; 32
females (47%)] undergoing IASC closure, being followed
up for 16.8 (±9.9; 6–42) months. Two patients with AF
previous to device implantation had been excluded.
Parameters analyzed included age and gender as well as
presence of coronary artery disease, hypertension, atrial
size, body mass index, device size, and presence of residual
shunt. Device size was normalized to maximal disk
diameter as declared by the manufacturer.
Results The incidence of new onset AF was 10.3% in the
ﬁrst 6 months after IASC closure. The only two predictors
linked to AF were device size (P = 0.002) and, although
not reaching signiﬁcance level, right atrial dilatation
(P = 0.08).
Conclusion Occluder size was the only signiﬁcant pre-
dictor of post-procedural AF, especially after PFO closure.
Although there may be constraints (defect size, presence of
an atrial septal aneurysm) that may dictate implantation of
a larger device, it is reasonable to implant them ‘‘as large as
necessary, as small as possible’’. The inﬂuence of atrial
dimensions on post-procedural onset of AF must be further
investigated.
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Background
Although some reports describing the incidence of atrial
ﬁbrillation (AF) after closure of interatrial septal commu-
nications (IASC) have been published, most of them have
used a few well-established devices [1–3]. Some limita-
tions of these studies have been acknowledged [1], the
larger study choosing to omit analyzing atrial and device
size as predictors of new onset AF. In addition, other
parameters as presence of hypertension, coronary artery
disease or body mass index have been inconsistently
reported [1–3]. By far, the largest number of new onset AF
occurs in the ﬁrst months after device implantation [1, 2].
Knowledge concerning the incidence of AF after closure of
IASC should be diligently sought, as AF remains one of the
important causes of cerebrovascular events if not promptly
treated. We aimed to deﬁne the incidence of AF in the ﬁrst
6 months after implantation of a variety of contemporary
devices in a real-world setting, analyzing more possible
predictors of AF than has been the case to date.
Methods
Study population
All patients (n = 70,) who underwent transcatheter IASC
closure by the author from January 2006 to December 2008
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septal defect (ASD), one because he had presented with
recurrent episodes of AF before closure, another because
she had undergone catheter ablation before closure and
remained in sinus rhythm. All patients had undergone 24 h
ECG monitoring prior to device implantation. For the
purpose of this study, frequent atrial ectopics were deﬁned
as[1% of all beats during 24 h. Patients experiencing more
than 30 consecutive beats (excluding supraventricular and
re-entry tachycardia and typical atrial ﬂutter) were deﬁned
as having intermittent AF, with the temporal inclusion cri-
teria as described previously [1]. Patient characteristics and
devices used are summarized in Table 1.
Left atrial measurement was taken in the short axis
parasternal view. Although patients undergoing echocar-
diography at our institution usually had a 4-chamber long
and short axis measurement of right atrial dimensions,
some patients were referred by an external cardiologist or
hospital and lacked these measurements. The right atrium
was thus assessed to be visually enlarged or ‘‘normal’’.
Device selection, description, and implantation
Device size selection was based on transoesophageal
echocardiography sizing in the ﬁrst 30 patients, until un-
dersizing was probably partially causal in subacute device
embolization in one patient [4]. In all following patients,
device size selection was based on intra-interventional
balloon sizing. Device size was reported as diameter of the
largest disk as declared by the manufacturer. For example,
an Amplatzer
 device used for closure of a 36 mm ASD,
has a left atrial disk diameter of 52 and a right atrial disc
diameter of 46 mm; in this case, 52 mm was chosen as the
device size in our study. All devices were implanted and no
in-hospital complications occurred. The devices used are
shown in Table 2.
Follow up
The follow-up period was 16.8 (±9.9; 6–42) months. Mid-
term complications (excluding AF) were one device dis-
location that could be retrieved percutaneously [4] and one
arteriovenous ﬁstula was treated surgically on an ambula-
tory basis. Treatment after device implantation consisted of
Clopidogrel for 3 months, acetyl salicylic acid, and pro-
phylaxis against infectious endocarditis for 12 months. All
patients were seen by the author at least 1 and 6 months
after implantation, for transthoracic and transesophageal
echocardiography, respectively. All patients and referring
physicians were asked to report any change in symptoms or
clinical status, with special emphasis on palpitations.
Patients suspected of having or those with documented AF
were followed up by 12-lead ECG and/or Holter monitor-
ing. The rhythm in asymptomatic patients was documented
by a resting ECG and by monitoring during echocardiog-
raphy at least twice on both follow-up visits by the
examining cardiologist. None of the asymptomatic patients
had 24 h ECG monitoring.
Continuous data are presented as a mean ±SD and
range, and compared using a paired Student’s t test. All
data were analyzed using the StatView 5.0
 program, SAS
systems
TM, Cary, NC, USA).
Results
Incidence of AF and treatment
Seven patients (10.3%) experienced one or more episodes
of AF with palpitations as presenting symptom in all seven
and additionally dyspnea and precordial pain in three. All
episodes occurred in the ﬁrst 6 months after device
implantation (1–24 days; 14.6 ± 9.6). None of the epi-
sodes was intermittent at presentation. The patient experi-
encing AF peri-interventionally was immediately
cardioverted and treated with Betablockers. One patient was
on oral anticoagulation because of recurrent deep venous
thrombosis and was cardioverted and given Betablocker.
Two patients with a CHADS 2 score B1w e r eg i v e n
Table 1 Patient characteristics
All patients
(women)
Age in years Hypertension Coronary artery disease LA size RA dilated Residual shunt
68 (32; 47%) 53.6 ± 15.1; 24–83 12 (17.6%) 6 (8.8%) 3.52 ± 0.52; 2.1–4.9 11 (16.1%) 3 (4.4%)
LA left atrium size in mm (upper limit of normal 40 mm)
RA right atrium (semi quantitative assessment: dilated versus not dilated. Pre-intervention dimensions available only in 12 patients)
Table 2 Device types used
Amplatzer
 Occlutec
 Solysafe
 Premere
 Cardia

Total
number
28 20 9 8 3
AF 1 (3.6%) 5 (20%) 1 (11%) 0 0
AF number of patients having experienced atrial ﬁbrillation after
device implantation
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converted spontaneously within a few days. Three patients
with a CHADS 2 score[1 were put on oral anticoagulation,
Amiodarone, and cardioverted. In one patient, cardioversion
had to be applied twice after a recurrence and the seventh
patient also experienced a recurrence and is receiving oral
anticoagulation with established AF, she had declined a
second cardioversion and Amiodarone medication. No
patient experienced any complication due to AF (no embolic
events, cardiac decompensation or syncope). Except for the
latter patient, all antiarrhythmic medication and oral anti-
coagulation were stopped after 2 months, after a 24 h-ECG.
Predictors of AF
The following parameters showed to bear no relation to the
new onset of AF after closure of an IASC: residual shunt,
hypertension, body mass index, coronary artery disease,
gender, age, and left atrial size. Signiﬁcance for right atrial
size as a predictor for AF was narrowly missed (P = 0.08).
The only signiﬁcant predictor of AF was found to be device
size (Table 3). Four out of seven patients experiencing post
closure AF had right atrial enlargement. Of the 68 patients
studied, 62 (91.2%) had a patent foramen ovale (PFO) and 6
(8.8%)anASD.Of the latter,one patient (17%)experienced
AF after defect closure, the other six patients developing AF
hadaPFO(9.6%;P = ns).Frequentatrialectopicshadbeen
found in two patients that developed AF after IASC, and in
four patients that remained free of AF (P = ns).
Discussion
The incidence of AF after closure of an IASC seems to be
higher in our series than in others published so far [1–3].
This may be a bias due to the numbers studied, or to dif-
ferent deﬁnition, selection, or follow-up criteria. Basically,
most studies suspect some factors to be implicated in the
occurrence of AF in this setting. Left atrial and device size
[3] are cited by some, residual shunting [1] by others, yet
the data are not always congruent.
The three patients (4.4%) in our series showing a min-
imal [2] and moderate [1] residual shunt 6 months after
closure, deﬁned as described previously [5], did not
develop AF. Atrial dysrhythmias after IASC closure may
be due to an inﬂammatory response of the atrial myocar-
dium [1]. New macro-reentry circuits may be favored [1];
more so when the left atrial disk is in the vicinity of right
pulmonary veins ostia. Alternatively, mechanical irritation
by the device, analogous to catheter-induced atrial dys-
rhythmias sometimes seen during right heart catheteriza-
tion, may occur. The larger the size and the contact surface
of the device with the atrial walls, the larger the potential
for mechanical irritability. One of the reasons why in our
series, left atrial dilatation did not correlate with AF
development may be that in all nine patients with left atrial
enlargement, device sizes happened not to exceed 25 mm
(2 device diameters of 15 mm, one of 20 mm and 6 of
25 mm). Of the 11 patients with enlarged right atrial
dimensions, 4 experienced postprocedural AF, 3 of them
with device sizes of 30 mm diameter, and one of 35 mm
(the only patient with ASD and AF). Two patients with
ASD and very large devices (48 and 52 mm) remained in
sinus rhythm; the right atrial dimensions regressed to
normal at 6 months’ follow-up. The three patients with RA
enlargement and AF had received 30 mm devices. Four of
the ﬁve remaining patients with RA enlargement remaining
in sinus rhythm had a 25 mm, the last one a 30 mm device.
A partial explanation for the apparent contradiction why
only one out of six patients with a large ASD developed AF
after closure of the defect may be that, in contrast to PFO,
atrial volume overload is seen with signiﬁcant shunting in
ASD, leading to atrial enlargement. Often there is a rapid
decrease of atrial dimensions after ASD closure [6, 7],
probably by leading to decrease in wall tension and
reduction of the arrhythmic substrate. This is also exem-
pliﬁed by one of the patients in our series, who had been
excluded because of persistent AF before ASD closure.
Immediately after device implantation, left atrial size was
5.1 cm and right atrial size 5.8 9 6 cm. On the ﬁrst
transthoracic examination 1 month post implantation, the
left atrium measured 4.8 cm and the right one 5 9 5.4 cm.
The patient was cardioverted and remained in sinus
rhythm. A second reason may also be related to the (literal)
contact area between the device and the atrial wall. In a
large ASD, the defect itself is no substrate for ‘‘contact-
dysrhythmia’’, the active interface ‘‘device-atrial tissue’’ is
limited by the surface of the rim covered by the device
Table 3 Predictors of atrial ﬁbrillation
Variable No AF AF P
Age in years 53 ± 15.4; 24–83 58 ± 13; 32–71 NS; 0.8
Gender (F) 28 (45.9%) 4 F (57%) NS
BMI 25.3 ± 4.4; 18.8–37.8 24 ± 2; 21.5–27.5 NS; 0.17
LA size 3.5 ± 0.56; 2.1–4.9 3.6 ± 0.38; 3–4.1 NS; 0.24
RA dilatation 7/61 (11.5%) 4/7 (57%) NS; 0.08
Device size
a 26.4 ± 5.6; 15–52 31.6 ± 2.7; 30–36 0.002
Hypertension 11/61 0/7 NA
CAD 4/61 2/7 NS; 0.17
Residual shunt 3/61 0/7 NA
AF new onset atrial ﬁbrillation after device implantation, BMI body
mass index, CAD coronary artery disease, NA Not analyzed, NS not
signiﬁcant
a Diameter of largest disc of device used as declared by manufacturer
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123edges. For example, for an ASD measuring 32 mm, we use
a 32 mm Amplatzer
 device with a left atrial disc diameter
of 46 mm. The surface area of the device would maximally
be 16.6 cm
2 (pr
2 = 3.14 9 [2.3]
2), of which 8.04 cm
2
(3.14 9 [1.8]
2) would cover the defect, leaving 8 cm
2
device rim in contact with atrial myocardium. This is not
much more than the 7.1 cm
2 (3.14 9 [1.5]
2) of a 30 mm
Amplatzer
 device used to cover a slit-like PFO with an
atrial septal aneurysm. A study reporting on symptomatic
AF after ASD (not PFO) closure quotes an incidence of
15% [8], which is more in line with our results.
One of the devices seemed to be numerically associated
with higher rates of AF (Table 2); statistically this was not
signiﬁcant. At this stage, it would be purely speculative to
link any physical characteristic (stiffness of metal, device
bulkiness, etc) with occurrence of AF in this small series.
Limitations
Obviously, caution has to be exerted when talking about
statistical signiﬁcance and while dealing with small patient
numbers. Also, the small numbers render a multivariate
analysis inapplicable.
Dimensions of the RA have only be qualiﬁed, not
numerically quantiﬁed, because most echocardiography
studies of patients referred for PFO closure described the
RA either as enlarged or normal. Then again, the long axis
dimensions of the LA were not systematically registered,
even in our patients. Although theoretically some sponta-
neously converted episodes of AF may have been missed,
despite routine 24 h ECG in all patients pre-procedurally,
our feeling is rather that post IASC episodes have been
underreported in the literature to date. It is more than
probable that not all transient episodes of AF can be
attributed to an anatomical or mechanical cause. There may
be other less tangible factors as exempliﬁed by one of our
younger patients who reported with AF after a week of
overwork followed by indulgence of excessive alcohol over
the weekend [9].
Conclusion
More data on the incidence of postprocedural AF after
IASC are needed as its incidence seems to be underre-
ported. This may be due to the fact that the majority of
these episodes are transient and asymptomatic, yet they
remain potentially dangerous. Occluder size was the only
signiﬁcant predictor of post-procedural AF, especially after
PFO closure. Although there are some obvious constraints
(defect size, presence of an atrial septal aneurysm, etc.) that
sometimes may dictate implantation of a larger device, it
may be reasonable to implant occluders ‘‘as large as nec-
essary, as small as possible’’. Larger studies examining the
correlation between atrial and device size on one hand and
AF on the other, are necessary.
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